ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Acorda Buys CNS Drug Firm Biotie

by Ann M. Thayer
January 25, 2016 | APPEARED IN VOLUME 94, ISSUE 4

Acorda Therapeutics will pay $363 million in cash to acquire Finland’s Biotie Therapies, a developer of central nervous system drugs. Acorda will gain tozadenant, a small-molecule adenosine A2A receptor antagonist in Phase III clinical trials for treating Parkinson’s disease, and SYN120, a small-molecule 5-HT6/5-HT2A dual receptor antagonist for Parkinson’s-related dementia in Phase II trials. Ardsley, N.Y.-based Acorda plans to keep Biotie’s South San Francisco location and staff but is considering the future of the firm’s Finnish headquarters.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment